Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

ClinicalTrials.gov ID

NCT06080074

Lead Sponsor

Stanford UniversityOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

50Estimated

Last Update Posted

Aug 10, 2026Actual

Start Date

Apr 15, 2025Actual

Primary Completion Date

Sep 2027Estimated

Completion Date

Sep 2029Estimated

Official Title

Multicenter Trial to Evaluate the Safety and Effectiveness of the Cardiohelp System for up to 30 Days of Support in Children With Severe Cardiac Failure

Brief Summary

There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to:

1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of support in children with severe heart failure with the goal to support its FDA clearance in children.
2. To evaluate heparin versus bivalirudin as the primary blood thinner (anticoagulant) in a randomized trial of children supported with the Cardiohelp ECMO System with the goal to plan a phase III (pivotal) randomized clinical trial

The main questions the Cardiohelp single-arm trial seeks to answer are:

• What is the safety and effectiveness of the Cardiohelp device for pediatric ECMO?
• Should the Cardiohelp device be FDA-cleared for children based on the results of the study?
• What are the optimal performance specifications of the Cardiohelp device in children?

The main questions the blood thinner randomized trial seeks to answer are:

• Which blood thinner is more promising (i.e., more effective and safer) in children on the Cardiohelp device?
• How should a pivotal trial of heparin vs. bivalirudin be designed so it is the most informative and efficient to determine the best blood thinner?

Children who are receiving the Cardiohelp device will be approached and consented to participate if interested. For the Cardiohelp device trial, participants will undergo a standardized data collection to estimate survival to 30 days and the prevalence of serious adverse events like stroke, bleeding, and hemolysis. For the blood thinner randomized trial, participants will be randomized 1:1 to blood thinner strategy to determine which blood thinner has the fewest bleeding and clotting complications.

For the Cardiohelp single-arm trial, participant outcomes will be compared to performance goals (PG) derived from the ECMO literature. For the blood thinner randomized trial, the amount of bleeding and clotting will be measured.

The study is funded by an R01 grant from the FDA's Office of Orphan Product Development (OOPD).

Detailed Description

This is a multicenter clinical trial to evaluate the safety and effectiveness of the Cardiohelp System for up to 30 days of support in children with severe cardiac failure. The trial includes a secondary randomized study comparing heparin versus bivalirudin anticoagulation according to standard treatment protocols.

Despite more than 50 years of ECMO use that carries up to 50% mortality, no standalone ECMO device has ever received FDA clearance for pediatric ECMO. All ECMO use in children is off-label, which may contribute to substantial mortality and complications, as well as wide center-to-center variation in ECMO practices that lacks an evidence base. Additionally, while two anticoagulants (heparin and bivalirudin) are commonly used in ECMO circuits, the optimal choice remains unknown-specifically, which anticoagulant is associated with the fewest circuit clots and least bleeding.

This study, funded by an R01 clinical trials Orphan Grant from the FDA, seeks to change the current status quo. By collecting systematic safety and effectiveness data on the Cardiohelp Device, we aim to determine whether it is safe and effective enough to become the first standalone ECMO device to receive FDA clearance for up to 30 days of support in children. The FDA clearance decision will be based on how the Cardiohelp performs relative to several key performance benchmarks drawn from the published ECMO literature, which the FDA has jointly agreed upon. These benchmarks include overall survival without severe stroke, degree of hemolysis (red blood cell breakdown), frequency of circuit change due to thrombus or device malfunction, stroke rate, and kidney injury rate.

For the anticoagulant randomized trial, we will collect systematic data on clotting and bleeding complications associated with each anticoagulant. As a Phase II study, the goal is not to reach a final answer, but to design a Phase III (pivotal) trial that is as informative and efficient as possible for addressing this critical question in the field of ECMO.

Tertiary goals of the study are: (1) to determine the optimal performance range (i.e., device specifications) for the Cardiohelp device in children to inform an eventual FDA label and Instructions for Use (IFU); and (2) to provide the FDA with a predicate device to support FDA clearance of other ECMO systems under 510(k) regulation, as no predicate devices currently exist to support such regulatory comparisons.

• Heart Failure
• Cardiogenic Shock
• Congenital Heart Disease
• Cardiomyopathies

• Cardiohelp device (VA-ECMO)
• Heparin
• Bivalirudin

Ages Eligible for Study

Child (0-17)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Age 0 to 16 years of age (i.e., <17 years)
2. Body weight 2.5 to 80 kilograms
3. VA-ECMO use for primary cardiac failure using the Cardiohelp system.
4. First ECMO run during the current hospitalization
5. Written informed consent from the parent or legally appointed representative (LAR)

Exclusion Criteria:Children must not meet any of the following exclusion criteria after ECMO cannulation and immediately prior to consent:

1. Gestationally-corrected age <37 weeks
2. Bleeding or coagulopathy that is a contraindication to anticoagulation
3. Irreversible renal, hepatic or lung failure
4. Stroke or uncertain neurological status within the past 30 days
5. Severely malnourished
6. Use of an ECMO system other than the Cardiohelp
7. VV-ECMO or ECMO for primary respiratory failure
8. Goals of patient to focus on comfort measures only.
9. Failure to separate from cardiopulmonary bypass
10. Allergy or contraindication to receiving UFH or bivalirudin as a primary anticoagulant on ECMO.
11. Patients who are pregnant or breastfeeding.
12. Unable to undergo randomization within 30 hours following ECMO cannulation (randomized cohort only)

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Stanford UniversityOTHER

Collaborators

Boston Children's HospitalOTHER

Duke UniversityOTHER

FDA Office of Orphan Products DevelopmentFED

ec2335@cumc.columbia.edu(212) 305-8458

Sirine.Baltagi@UTSouthwestern.edu

• EXCOR® Pediatric VAD Anticoagulation IDE

  NCT03702192

  WithdrawnInterventionalNot ApplicableUpdated Oct 31, 2019
• The Prospective, Multicenter, Randomized Controlled Trial of the VentriCure Interventional Left Ventricular Assist System

  NCT07675005

  Not yet recruitingInterventionalNot ApplicableUpdated Jun 30, 2026
• Evaluate the Effectiveness and Safety of the OmniHeart 4.0 Percutaneous Ventricular Assist Device in Providing Hemodynamic Support for Patients Undergoing High-risk Percutaneous Coronary Intervention (PCI).

  NCT07622446

  Active, not recruitingInterventionalNot ApplicableUpdated Jun 10, 2026
• Phimume® Percutaneous Left Ventricular Assist System Study

  NCT06639321

  Not yet recruitingInterventionalNot ApplicableUpdated Oct 15, 2024
• Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO

  NCT03318393

  CompletedInterventionalPhase 4Updated Jan 31, 2023
• ECMO Hemostatic Transfusions in Children

  NCT05796557

  CompletedInterventionalPhase 4Updated May 31, 2025